Nicotine pouches offer huge promise—so long as the U.S. doesn’t repeat its mistake with vaping

Max Cunningham, CEO of Sesh+, positions tobacco-free, U.S.-made nicotine pouches as a regulated harm-reduction alternative to combustible cigarettes and the unregulated vape market that produced public-health problems and JUUL’s regulatory fallout; the product is independently lab-tested, backed by 8VC, and currently skews older (average customer >35) with early Rutgers data showing low uptake among new users. He warns that counterfeit and bootleg products from abroad, weak retail education and youth access are the primary commercial and reputational risks, and calls for industry-wide product-verification technology, stronger enforcement and supportive age-restriction policy (citing the U.S. age-21 law and the UK Tobacco and Vapes Bill) to prevent repeat mistakes. For investors, the category presents a sizable opportunity in nicotine harm reduction but execution hinges on regulation, supply-chain integrity and the ability to prevent illicit competition and youth adoption.

Analysis

The article frames combustible cigarettes and an unregulated vaping market as dual public-health failures, noting that "more than 500,000 Americans still die each year from smoking-related illnesses" and that counterfeit and bootleg vapes—often imported from China—have caused illness and youth uptake. The author, Max Cunningham, positions Sesh+ (backed by 8VC) as a U.S.-manufactured, tobacco-free nicotine pouch alternative created after personal experience with vaping addiction and regulatory fallout from JUUL.

Sesh+ emphasizes independent lab testing for contaminants (including heavy metals) and strict U.S. manufacturing controls; the company reports an average customer age over 35 and cites a Rutgers study finding that new nicotine uptake from pouches remains very low. The author asserts harm reduction is feasible because combustion, not nicotine per se, drives smoking-related disease, while poor transparency drove the vaping crisis.

Primary commercial and regulatory risks are counterfeit products, weak retailer education, youth access, and hostile or uneven regulatory actions by bodies like the FDA; the piece specifically cites supportive policy options including the U.S. age-21 law and the U.K. Tobacco and Vapes Bill proposal. Market signals show a mildly positive, cautious sentiment (sentiment_score 0.28, market_impact_score 0.25), implying investor interest exists but execution depends on regulation, supply-chain integrity and adoption of product-verification technology.

Key Decisions for Investors

• Perform targeted diligence on nicotine-pouch businesses that can demonstrate U.S. manufacturing, independent contaminant testing, and reputable backers (such as 8VC) before allocating capital
• Monitor regulatory milestones closely—FDA guidance, enforcement actions, and the outcome of the U.K. Tobacco and Vapes Bill—as they will be primary catalysts or de-risking events for the category
• Prioritize exposure to companies or service providers with proven anti-counterfeit and product-verification technology and documented retailer-education programs, and avoid or hedge pure-play unregulated vape exposure
• Require pre-investment KPIs on youth uptake metrics, independent lab results, and supply-chain traceability as conditions for new or increased positions